KR960700039A - β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor) - Google Patents

β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)

Info

Publication number
KR960700039A
KR960700039A KR1019950702775A KR19950702775A KR960700039A KR 960700039 A KR960700039 A KR 960700039A KR 1019950702775 A KR1019950702775 A KR 1019950702775A KR 19950702775 A KR19950702775 A KR 19950702775A KR 960700039 A KR960700039 A KR 960700039A
Authority
KR
South Korea
Prior art keywords
cyclodextrin
carbonic anhydrase
anhydrase inhibitor
eye
effective
Prior art date
Application number
KR1019950702775A
Other languages
English (en)
Inventor
조나단 씨. 자빗
노먼 비. 자빗
피터 맥도넬
Original Assignee
조나단 씨. 자빗
노먼 비. 자빗
피터 맥도넬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조나단 씨. 자빗, 노먼 비. 자빗, 피터 맥도넬 filed Critical 조나단 씨. 자빗
Publication of KR960700039A publication Critical patent/KR960700039A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

유효량의 탄산 탈수효소 저해제 및 눈에 국소적으로 동시 투여될 때 탄산 탈수 효소 저해제의 생체이용가능성을 증가시키는데 효과적인 양의

Description

-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (27)

  1. 유효량의 탄산 탈수효소 저해제 및 눈에 국소적으로 동시 투여될때 탄산 탈수 효소 저해제의 생체이용가능성을 증가시키는데 효과적인 양의 비결정성-시클로덱스트린으로 이루어진 국소 투여를 위한 안과용 조성물을 함유하는 안과용 점안제 디스펜서.
  2. 유효량의 탄산 탈수효소 저해제 및 조성물 중의 탄산 탈수효소 저해제의 용해도를 비결정성-시클로덱스트린의 부재하의 그의 용해도에 비해 증가시키는데 효과적인 양의 비결정성-시클로덱스트린의 이루어진 국소 투여를 위한 안과용 조성물을 함유하는 안과용 점안제 디스펜서.
  3. 제1항에 있어서, 탄산 탈수효소 저해제가 헤테로시클릭 술폰아미드인 점안제 디스펜서.
  4. 제3항에 있어서, 헤테르시클릭 술폰아미드가 아세타졸아미드, 메타졸아미드 또는 에톡스졸아미드인 점안제 디스펜서.
  5. 제4항에 있어서, 아세타졸아미드 또는 메타졸아미드의 양이 눈에 국소 투여될때 안내압을 20%이상 감소시키는데 효과적인 점안제 디스펜서.
  6. 제5항에 있어서, 아세타졸아미드의 양이 약 0.1 내지 약 3.5w/V%인 점안제 디스펜서.
  7. 제1항에 있어서,-시클로덱스트린이 히드록시프로필--시클로덱스트린인 점안제 디스펜서.
  8. 제7항에 있어서, 히드록시프로필--시클로덱스트린의 양이 약 40-60w/v%인 점안제 디스펜서.
  9. 제1항에 있어서,-시클로덱스트린 유도체가 히드록시프로필--시클로덱스트린이고, 탄산 탈수효소 저해제가 아세타졸아미드 또는 메타졸아미드인 점안제 디스펜서.
  10. 제9항에 있어서, 히드록시프로필--시클로덱스트린의 양이 약 40-60w/v%인 점안제 디스펜서.
  11. 유효량의 탄산 탈수효소 저해제 및 눈에 국소적으로 동시 투여될때 탄산 탈수 효소 저해제의 생체이용가능성을 증가시키는데 효과적인 양의 비결정성-시클로덱스트린으로 이루어진 국소 투여를 위한 안과용 조성물을 눈에 국소 투여하는 것으로 이루어지는, 탄산 탈수효소 저해제 투여에 의한 안 질환의 치료 방법.
  12. 제11항에 있어서, 눈에서의 액 분비를 억제하거나 또는 안내압 이상을 치료하는 방법.
  13. 제11항에 있어서, 녹내장을 치료하는 방법.
  14. 제11항에 있어서, 탄산 탈수효소 저해제가 헤테로시클릭 술폰아미드인 방법.
  15. 제14항에 있어서, 헤테로시클릭 술폰아미드가 아세타졸아미드 또는 메타졸아미드인 방법.
  16. 제11항에 있어서,-시클로덱스트린이 히드록시프로필--시클로덱스트린인 방법.
  17. 제16항에 있어서, 히드록시프로필--시클로덱스트린의 양이 약 40-60w/v%인 방법.
  18. 제11항에 있어서,-시클로덱스트린이 히드록시프로필--시클로덱스트린이고 탄산 탈수효소 저해제가 아세타졸아미드 또는 메타졸아미드인 방법.
  19. 제18항에 있어서, 녹내장을 치료하는 방법.
  20. 유효량의 탄산 탈수효소 저해제 및 비결정성-시클로덱스트린 40-60w/v%로 이루어지며, 상기-시클로덱스트린의 양이 국소 투여시에 탄산 탈수효소 저해제의 생체이용가능성을 증가시키는데 효과적인 양인 국소 투여를 위한 안과용 조성물.
  21. 제20항에 있어서,-시클로덱스트린이 히드록시프로필--시클로덱스트린인 조성물.
  22. 제20항에 있어서, 탄산 탈수효소 저해제가 아세타졸아미드 또는 메타졸아미드인 조성물.
  23. 제21항에 있어서, 탄산 탈수효소 저해제가 아세타졸아미드 또는 메타졸아미드인 조성물.
  24. 제20항에 있어서, 비경구 투여에 유용하지 않은 조성물.
  25. 유효량이 안과적 활성제 및 눈에 국소 투여될 때 안과적 활성제의 생체이용가능성을 증가시키는데 효과적인 양의 비결정성-시클로덱스트린으로 이루어진 국소 투여를 위한 안과용 조성물을 눈에 국소 투여하는 것으로 이루어지는, 탄산 탈수효소 저해제 투여에 의한 안 질환의 치료 방법.
  26. 제25항에 있어서, 활성제가 스테로이드인 방법.
  27. 유효량의 탄산 탈수효소 저해제 및 눈에 국소적으로 동시 투여될때 탄산 탈수효소 저해제의 생체 이용가능성을 증가시키는데 효과적인 양의 비결정성-시클로덱스트린으로 이루어진 국소 투여를 위한 안과용 조성물을 함유하는 국소투여를 위한 안과용 어플리케이터.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950702775A 1993-01-05 1994-01-05 β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor) KR960700039A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93593A 1993-01-05 1993-01-05
US08/000,935 1993-01-05
PCT/US1994/000339 WO1994015582A1 (en) 1993-01-05 1994-01-05 Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor

Publications (1)

Publication Number Publication Date
KR960700039A true KR960700039A (ko) 1996-01-19

Family

ID=21693635

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702775A KR960700039A (ko) 1993-01-05 1994-01-05 β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)

Country Status (8)

Country Link
US (1) US5494901A (ko)
EP (1) EP0678016A1 (ko)
JP (1) JPH08509205A (ko)
KR (1) KR960700039A (ko)
AU (1) AU6086194A (ko)
BR (1) BR9405698A (ko)
CA (1) CA2153268A1 (ko)
WO (1) WO1994015582A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789435A (en) * 1995-05-22 1998-08-04 Advanced Research And Technology Institute Method to increase retinal and optical nerve head blood flow velocity in order to preserve sight
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
US6046223A (en) * 1996-02-26 2000-04-04 Advanced Research & Technology Institute Treatment of macular edema
EP1109581A1 (en) 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
AU2004229291A1 (en) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
CN100345594C (zh) * 2004-01-19 2007-10-31 无锡杰西医药科技有限公司 乙酰唑胺滴眼液
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
GB2413282B (en) * 2004-04-23 2009-01-14 Henderson Morley Plc DNA Viral Infections
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
AU2006249816A1 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
CN106822174B (zh) * 2016-12-19 2019-10-11 上海大学 基于温敏环糊精的碳酸酐酶抑制剂及其制备方法
EP3505154B1 (en) * 2017-12-26 2022-04-06 Industrial Technology Research Institute Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438123A (en) * 1980-03-04 1984-03-20 Merck & Co., Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4619939A (en) * 1980-07-09 1986-10-28 University Of Florida Process for reducing intraocular pressure
WO1982000096A1 (en) * 1980-07-09 1982-01-21 Maren T Process for reducing intraocular pressure
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
US4824866A (en) * 1987-02-02 1989-04-25 Riker Laboratories, Inc. Anti-glaucoma use of trifluoromethanesulfonamide
GB2203039B (en) * 1987-03-02 1990-10-24 American Cyanamid Co Stable ophthalmic preparations containing acetazolamide
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE68901043D1 (de) * 1988-01-14 1992-04-30 Akzo Nv Waessriges pharmazeutisches praeparat.
DE68906942T3 (de) * 1988-03-29 1999-05-12 Univ Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
JPH0228112A (ja) * 1988-04-21 1990-01-30 Kaken Pharmaceut Co Ltd 点眼用眼圧調整剤
US4975428A (en) * 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
CA2017156A1 (en) * 1989-06-02 1990-12-02 Sotoo Asakura Preparation of fr115224 substance for parenteral administration
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
TW200402B (ko) * 1990-08-13 1993-02-21 Senju Pharma Co
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
CA2153268A1 (en) 1994-07-21
WO1994015582A1 (en) 1994-07-21
EP0678016A1 (en) 1995-10-25
US5494901A (en) 1996-02-27
BR9405698A (pt) 1995-11-21
AU6086194A (en) 1994-08-15
JPH08509205A (ja) 1996-10-01

Similar Documents

Publication Publication Date Title
KR960700039A (ko) β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)
JP7432654B2 (ja) 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法
US5891913A (en) Ophthalmic and aural compositions containing diclofenac potassium
JP3994089B2 (ja) 眼科学および鼻科学における適用のための薬学的組成物
ES2094688A1 (es) Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
AR011192A1 (es) Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma
JP2005521691A (ja) シクロデキストリン化合物及び塩化セチルピリジニウムを含有する眼科用抗菌性薬物製剤
ATE228125T1 (de) Alpha-azacyclomethylchinolinderivate zur behandlung von harninkontinenz
KR890701084A (ko) 점안 싸이클로스포린(cyclspoorin)의 조성 및 투여방법
JP2000508646A (ja) 眼における滞留時間の長い目薬組成物
US20070166402A1 (en) Compositions, methods and kits for removing debris from an ocular area
EP0280797A2 (en) Medicaments for treatment of ocular inflammation
US5435998A (en) Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents
PL185661B1 (pl) Kompozycja antyseptyczna do oczu
JP5532609B2 (ja) 眼科用組成物及び刺激緩和剤
CA2487332C (en) Quaternised ammonium cyclodextrin compounds for use as antimicrobial agents, preservatives and penetration enhancers
KR950703527A (ko) 프로스타글란딘 유도체
US5200180A (en) Pharmaceutical composition for the treatment of the human eye
EP0308460B1 (en) A composition for the topical treatment of glaucoma or ocular hypertension
JP4849288B2 (ja) 点眼剤及び涙液膜の安定化剤
KR940013505A (ko) 항 알레르기 점안제
JP2007070350A (ja) 眼粘膜適用製剤
JP2006089460A (ja) 眼科用粘稠化剤
KR920019767A (ko) 티아졸 유도체
Afouna et al. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid